Special Issue

New Trends in Precision Medicine

Message from the Guest Editor

Precision medicine has emerged as a powerful model that focuses on how biomolecular factors can influence individual responses to different medications/therapies affecting drug efficacy, side effects, and adverse events related to therapy. Although personalized medicine emerged from pharmacogenetics, it now covers many fields of healthcare. Personalized nanomedicine involving individualized drug selection and dosage profiling in combination with clinical and molecular biomarkers can ensure the maximal efficacy and safety of treatment. Accordingly, regenerative medicine and cellular therapy as the new fields of medicine use cellbased products in order to develop personalized treatments. The major hindrance to the development of such therapies is the handling of the associated "Big Data," to keep the databases updated. This Special Issue seeks research papers on various aspects related to the emerging field of precision medicine, dentistry, and oral health, covering different aspects of the basics of translational research, regenerative medicine, and personalized treatments.

Guest Editor

Prof. Dr. Salvatore Scacco

Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari "Aldo Moro", 70124 Bari, Italy

Deadline for manuscript submissions

closed (5 January 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/91666

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

<u>jpm</u>





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

